Form 4: SOPHIA GENETICS: CFO George Cardoza Receives Equity Awards

SOPHIA GENETICS SA announces equity awards to Chief Financial Officer George Cardoza, including restricted stock units and stock options, with vesting schedules extending to 2030.

Summary

• George Cardoza, Chief Financial Officer of SOPHiA GENETICS SA, received a grant of 112,936 restricted stock units (RSUs) on April 2, 2026.
• These RSUs are part of the Issuer's 2021 Equity Incentive Plan and represent a contingent right to receive ordinary shares.
• Vesting for the RSUs is structured with 25% vesting on April 2, 2027, and the remaining 75% vesting in equal quarterly installments through April 2, 2030.
• Additionally, Cardoza was granted a share option to purchase 164,671 ordinary shares at an exercise price of $5.04.
• This share option vests 25% on April 2, 2027, with the remainder vesting in equal monthly installments through April 2, 2030.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents standard executive compensation and retention practices, indicating management commitment, but provides no new financial performance data.

Positives

• Granting of equity awards to key management personnel like the CFO can indicate confidence in future company performance and a commitment to retaining talent.
• The vesting schedules for both RSUs and options are staggered over several years, aligning management's interests with long-term shareholder value.
• The share option has a defined exercise price, providing a clear potential upside for the executive.

Negatives

• The filing does not provide specific financial performance data, making it difficult to assess the immediate impact of these awards on the company's financial health.
• The value of the equity awards is contingent on the future performance of SOPHiA GENETICS SA's stock price.

Risks

• The value of the granted RSUs and options is subject to market fluctuations and the company's future stock performance.
• If the company does not meet performance expectations, the full value of these equity awards may not be realized by the reporting person.

Future Outlook

The equity awards are structured with vesting periods extending to April 2, 2030, indicating a long-term incentive for continued service and performance. The share option is exercisable until April 2, 2036.

Industry Context

StockSavvy.ai notes that the issuance of equity awards to senior executives, such as CFOs, is a common practice in the biotechnology and healthcare technology sectors to incentivize performance and align executive interests with long-term shareholder value. This aligns with industry trends for talent retention and performance-based compensation.

Stakeholder Impact

• Shareholders: The awards are designed to align executive interests with long-term shareholder value, potentially leading to improved company performance. However, the dilutive effect of issuing new shares upon vesting should be considered.
• Employees: May be seen as a positive sign of executive commitment, but no direct impact on other employees is detailed.
• Management: Directly benefits from the equity awards, contingent on continued service and company performance.

Next Steps

• Continued service by George Cardoza through the vesting dates to receive the full equity awards.
• Monitoring of SOPHiA GENETICS SA's stock performance to determine the value realized from these awards.

Key Dates

Keywords

SOPHIA GENETICS, SOPH, Form 4, Equity Awards, Restricted Stock Units, RSU, Stock Options, George Cardoza, CFO, Insider Trading, SEC Filing, Executive Compensation